Context on Sarepta Therapeutics after recent price moves

Sarepta Therapeutics (SRPT) has seen mixed share price moves recently, with a 1 day gain of about 1.5%, a 4.3% decline over the past week, and a roughly 25.9% rise over the past month.

Recent moves at Sarepta come after a mixed stretch, with short term share price momentum improving over the past month while the 1 year total shareholder return of about 55.8% remains sharply negative. This combination may hint at shifting sentiment around future growth potential and risk.

If Sarepta’s swings have you thinking about where else growth stories could emerge in healthcare, it may be worth scanning 36 healthcare AI stocks as a starting shortlist.

With Sarepta trading near US$22.23 after a long stretch of weak multi year returns but a recent 1 month rebound, is the market still underestimating its rare disease pipeline, or already pricing in any future growth?

Most Popular Narrative: 3% Overvalued

The most followed narrative currently places Sarepta’s fair value at about $21.65, just below the last close at $22.23, which suggests only a modest gap between price and modelled expectations.

The analysts have a consensus price target of $21.65 for Sarepta Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $38.0, and the most bearish reporting a price target of just $5.0.

Want to understand what kind of revenue path, margin rebuild and future earnings multiple would support that fair value instead of today’s share price? The underlying narrative leans on a sharp swing from heavy losses to meaningful profits, plus a premium earnings multiple that sits well above the wider biotech group. Curious which assumptions really carry the weight in that calculation?

Result: Fair Value of $21.65 (OVERVALUED)

However, that story can quickly change if safety concerns around ELEVIDYS or slower than expected gene therapy uptake deepen, since both would directly challenge the current fair value case.

Another View: DCF Sends a Very Different Signal

The analyst target of $21.65 suggests Sarepta is only slightly above fair value, yet the SWS DCF model points to a very different picture, with an estimated value of $75.53 per share. That gap frames a big question for you: are future cash flows being underestimated, or are DCF assumptions too generous?

Next Steps

If this mix of cautious and optimistic signals feels hard to balance, take a closer look now and shape your own view using the 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If Sarepta is on your radar, do not stop there, the market is full of other opportunities that could fit your risk profile and goals.

• Target potential value opportunities by scanning 62 high quality undervalued stocks that pair stronger balance sheets with earnings power the market may be overlooking.
• Prioritise resilience with 73 resilient stocks with low risk scores and focus on businesses that score well on stability instead of chasing the loudest headlines.
• Spot earlier stage opportunities using the 32 elite penny stocks with strong financials that filter for stronger financials rather than pure speculation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.